APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Metformin-Pioglitazone

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metformin-Pioglitazone Market Outlook and Growth Opportunities 2026

Report ID 174012680422 December 2025198 pages

Choose your research edition.

Industry ResearchMetformin-Pioglitazone Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Metformin-Pioglitazone Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Metformin-Pioglitazone Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metformin-Pioglitazone Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Metformin-Pioglitazone Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Metformin-Pioglitazone market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metformin-Pioglitazone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metformin-Pioglitazone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metformin-Pioglitazone is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metformin-Pioglitazone market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metformin-Pioglitazone market include Takeda Pharmaceuticals, Teva, Sandoz, Mylan, Wellona Pharma, Torrent Pharmaceuticals, Neurocon Inc, MACLEODS and BLUE CROSS, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Metformin-Pioglitazone market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metformin-Pioglitazone and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metformin-Pioglitazone revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Metformin-Pioglitazone market.

Metformin-Pioglitazone Segment by Company

Takeda Pharmaceuticals

Teva

Sandoz

Mylan

Wellona Pharma

Torrent Pharmaceuticals

Neurocon Inc

MACLEODS

BLUE CROSS

Aurobindo Pharma

Metformin-Pioglitazone Segment by Type

Tablets: 15 mg pioglitazone/1000 mg metformin HCl

Tablets: 30 mg pioglitazone/1000 mg metformin HCl

Metformin-Pioglitazone Segment by Application

Hospital

Drug store

Metformin-Pioglitazone Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Metformin-Pioglitazone status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Metformin-Pioglitazone key companies, revenue, market share, and recent developments.

3. To split the Metformin-Pioglitazone breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Metformin-Pioglitazone market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metformin-Pioglitazone significant trends, drivers, influence factors in global and regions.

6. To analyze Metformin-Pioglitazone competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metformin-Pioglitazone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metformin-Pioglitazone and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metformin-Pioglitazone.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metformin-Pioglitazone industry.

Chapter 3: Detailed analysis of Metformin-Pioglitazone company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Metformin-Pioglitazone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Metformin-Pioglitazone in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metformin-Pioglitazone Industry Trends Table 2. Metformin-Pioglitazone Industry Drivers Table 3. Metformin-Pioglitazone Industry Opportunities and Challenges Table 4. Metformin-Pioglitazone Industry Restraints Table 5. Global Metformin-Pioglitazone Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metformin-Pioglitazone Revenue Share by Company (2021-2026) Table 7. Global Metformin-Pioglitazone Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Metformin-Pioglitazone Key Company Manufacturing Base & Headquarters Table 9. Global Metformin-Pioglitazone Company, Product Type & Application Table 10. Global Metformin-Pioglitazone Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Metformin-Pioglitazone by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablets: 15 mg pioglitazone/1000 mg metformin HCl Table 15. Significant Companies of Tablets: 30 mg pioglitazone/1000 mg metformin HCl Table 16. Global Metformin-Pioglitazone Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Metformin-Pioglitazone Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Metformin-Pioglitazone Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Metformin-Pioglitazone Sales Value Share by Type (2021-2026) Table 20. Global Metformin-Pioglitazone Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Drug store Table 23. Global Metformin-Pioglitazone Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Metformin-Pioglitazone Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Metformin-Pioglitazone Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Metformin-Pioglitazone Sales Value Share by Application (2021-2026) Table 27. Global Metformin-Pioglitazone Sales Value Share by Application (2027-2032) Table 28. Global Metformin-Pioglitazone Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Metformin-Pioglitazone Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Metformin-Pioglitazone Sales Value Share by Region (2021-2026) Table 31. Global Metformin-Pioglitazone Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Metformin-Pioglitazone Sales Value Share by Region (2027-2032) Table 33. Global Metformin-Pioglitazone Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Metformin-Pioglitazone Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Metformin-Pioglitazone Sales Value Market Share by Country (2021-2026) Table 36. Global Metformin-Pioglitazone Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Metformin-Pioglitazone Sales Value Market Share by Country (2027-2032) Table 38. Takeda Pharmaceuticals Company Information Table 39. Takeda Pharmaceuticals Business Overview Table 40. Takeda Pharmaceuticals Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Takeda Pharmaceuticals Metformin-Pioglitazone Product Portfolio Table 42. Takeda Pharmaceuticals Recent Development Table 43. Teva Company Information Table 44. Teva Business Overview Table 45. Teva Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Teva Metformin-Pioglitazone Product Portfolio Table 47. Teva Recent Development Table 48. Sandoz Company Information Table 49. Sandoz Business Overview Table 50. Sandoz Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Sandoz Metformin-Pioglitazone Product Portfolio Table 52. Sandoz Recent Development Table 53. Mylan Company Information Table 54. Mylan Business Overview Table 55. Mylan Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Mylan Metformin-Pioglitazone Product Portfolio Table 57. Mylan Recent Development Table 58. Wellona Pharma Company Information Table 59. Wellona Pharma Business Overview Table 60. Wellona Pharma Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Wellona Pharma Metformin-Pioglitazone Product Portfolio Table 62. Wellona Pharma Recent Development Table 63. Torrent Pharmaceuticals Company Information Table 64. Torrent Pharmaceuticals Business Overview Table 65. Torrent Pharmaceuticals Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Torrent Pharmaceuticals Metformin-Pioglitazone Product Portfolio Table 67. Torrent Pharmaceuticals Recent Development Table 68. Neurocon Inc Company Information Table 69. Neurocon Inc Business Overview Table 70. Neurocon Inc Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Neurocon Inc Metformin-Pioglitazone Product Portfolio Table 72. Neurocon Inc Recent Development Table 73. MACLEODS Company Information Table 74. MACLEODS Business Overview Table 75. MACLEODS Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. MACLEODS Metformin-Pioglitazone Product Portfolio Table 77. MACLEODS Recent Development Table 78. BLUE CROSS Company Information Table 79. BLUE CROSS Business Overview Table 80. BLUE CROSS Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. BLUE CROSS Metformin-Pioglitazone Product Portfolio Table 82. BLUE CROSS Recent Development Table 83. Aurobindo Pharma Company Information Table 84. Aurobindo Pharma Business Overview Table 85. Aurobindo Pharma Metformin-Pioglitazone Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Aurobindo Pharma Metformin-Pioglitazone Product Portfolio Table 87. Aurobindo Pharma Recent Development Table 88. Research Programs/Design for This Report Table 89. Authors List of This Report Table 90. Secondary Sources Table 91. Primary Sources List of Figures Figure 1. Metformin-Pioglitazone Product Image Figure 2. Global Metformin-Pioglitazone Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metformin-Pioglitazone Market Size (2021-2032) & (US$ Million) Figure 4. Global Metformin-Pioglitazone Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablets: 15 mg pioglitazone/1000 mg metformin HCl Image Figure 8. Tablets: 30 mg pioglitazone/1000 mg metformin HCl Image Figure 9. Global Metformin-Pioglitazone Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Metformin-Pioglitazone Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Metformin-Pioglitazone Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Drug store Image Figure 14. Global Metformin-Pioglitazone Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Metformin-Pioglitazone Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Metformin-Pioglitazone Sales Value Share by Application (2021-2032) Figure 17. Global Metformin-Pioglitazone Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Metformin-Pioglitazone Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Metformin-Pioglitazone Sales Value (2021-2032) & (US$ Million) Figure 20. North America Metformin-Pioglitazone Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Metformin-Pioglitazone Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Metformin-Pioglitazone Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Metformin-Pioglitazone Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Metformin-Pioglitazone Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Metformin-Pioglitazone Sales Value (2021-2032) & (US$ Million) Figure 26. South America Metformin-Pioglitazone Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Metformin-Pioglitazone Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Metformin-Pioglitazone Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Metformin-Pioglitazone Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets: 15 mg pioglitazone/1000 mg metformin HCl
  • Tablets: 30 mg pioglitazone/1000 mg metformin HCl
Applications
  • Hospital
  • Drug store
Companies covered
  • Takeda Pharmaceuticals
  • Teva
  • Sandoz
  • Mylan
  • Wellona Pharma
  • Torrent Pharmaceuticals
  • Neurocon Inc
  • MACLEODS
  • BLUE CROSS
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Metformin-Pioglitazone Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Metformin-Pioglitazone Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Metformin-Pioglitazone Market Dynamics
  1. 2.1 Metformin-Pioglitazone Industry Trends
  2. 2.2 Metformin-Pioglitazone Industry Drivers
  3. 2.3 Metformin-Pioglitazone Industry Opportunities and Challenges
  4. 2.4 Metformin-Pioglitazone Industry Restraints
3 Metformin-Pioglitazone Market by Company
  1. 3.1 Global Metformin-Pioglitazone Company Revenue Ranking in 2025
  2. 3.2 Global Metformin-Pioglitazone Revenue by Company (2021-2026)
  3. 3.3 Global Metformin-Pioglitazone Company Ranking (2024-2026)
  4. 3.4 Global Metformin-Pioglitazone Company Manufacturing Base and Headquarters
  5. 3.5 Global Metformin-Pioglitazone Company Product Type and Application
  6. 3.6 Global Metformin-Pioglitazone Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Metformin-Pioglitazone Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Metformin-Pioglitazone Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Metformin-Pioglitazone Market by Type
  1. 4.1 Metformin-Pioglitazone Type Introduction
  2. 4.1.1 Tablets: 15 mg pioglitazone/1000 mg metformin HCl
  3. 4.1.2 Tablets: 30 mg pioglitazone/1000 mg metformin HCl
  4. 4.2 Global Metformin-Pioglitazone Sales Value by Type
  5. 4.2.1 Global Metformin-Pioglitazone Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Metformin-Pioglitazone Sales Value by Type (2021-2032)
  7. 4.2.3 Global Metformin-Pioglitazone Sales Value Share by Type (2021-2032)
5 Metformin-Pioglitazone Market by Application
  1. 5.1 Metformin-Pioglitazone Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug store
  4. 5.2 Global Metformin-Pioglitazone Sales Value by Application
  5. 5.2.1 Global Metformin-Pioglitazone Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Metformin-Pioglitazone Sales Value by Application (2021-2032)
  7. 5.2.3 Global Metformin-Pioglitazone Sales Value Share by Application (2021-2032)
6 Metformin-Pioglitazone Regional Value Analysis
  1. 6.1 Global Metformin-Pioglitazone Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metformin-Pioglitazone Sales Value by Region (2021-2032)
  3. 6.2.1 Global Metformin-Pioglitazone Sales Value by Region: 2021-2026
  4. 6.2.2 Global Metformin-Pioglitazone Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Metformin-Pioglitazone Sales Value (2021-2032)
  7. 6.3.2 North America Metformin-Pioglitazone Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Metformin-Pioglitazone Sales Value (2021-2032)
  10. 6.4.2 Europe Metformin-Pioglitazone Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Metformin-Pioglitazone Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Metformin-Pioglitazone Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Metformin-Pioglitazone Sales Value (2021-2032)
  16. 6.6.2 South America Metformin-Pioglitazone Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Metformin-Pioglitazone Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Metformin-Pioglitazone Sales Value Share by Country, 2025 VS 2032
7 Metformin-Pioglitazone Country-level Value Analysis
  1. 7.1 Global Metformin-Pioglitazone Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metformin-Pioglitazone Sales Value by Country (2021-2032)
  3. 7.2.1 Global Metformin-Pioglitazone Sales Value by Country (2021-2026)
  4. 7.2.2 Global Metformin-Pioglitazone Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Metformin-Pioglitazone Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Metformin-Pioglitazone Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Metformin-Pioglitazone Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Metformin-Pioglitazone Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Metformin-Pioglitazone Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sandoz
  14. 8.3.1 Sandoz Company Information
  15. 8.3.2 Sandoz Business Overview
  16. 8.3.3 Sandoz Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sandoz Metformin-Pioglitazone Product Portfolio
  18. 8.3.5 Sandoz Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Metformin-Pioglitazone Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Wellona Pharma
  26. 8.5.1 Wellona Pharma Company Information
  27. 8.5.2 Wellona Pharma Business Overview
  28. 8.5.3 Wellona Pharma Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Wellona Pharma Metformin-Pioglitazone Product Portfolio
  30. 8.5.5 Wellona Pharma Recent Developments
  31. 8.6 Torrent Pharmaceuticals
  32. 8.6.1 Torrent Pharmaceuticals Company Information
  33. 8.6.2 Torrent Pharmaceuticals Business Overview
  34. 8.6.3 Torrent Pharmaceuticals Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Torrent Pharmaceuticals Metformin-Pioglitazone Product Portfolio
  36. 8.6.5 Torrent Pharmaceuticals Recent Developments
  37. 8.7 Neurocon Inc
  38. 8.7.1 Neurocon Inc Company Information
  39. 8.7.2 Neurocon Inc Business Overview
  40. 8.7.3 Neurocon Inc Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Neurocon Inc Metformin-Pioglitazone Product Portfolio
  42. 8.7.5 Neurocon Inc Recent Developments
  43. 8.8 MACLEODS
  44. 8.8.1 MACLEODS Company Information
  45. 8.8.2 MACLEODS Business Overview
  46. 8.8.3 MACLEODS Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  47. 8.8.4 MACLEODS Metformin-Pioglitazone Product Portfolio
  48. 8.8.5 MACLEODS Recent Developments
  49. 8.9 BLUE CROSS
  50. 8.9.1 BLUE CROSS Company Information
  51. 8.9.2 BLUE CROSS Business Overview
  52. 8.9.3 BLUE CROSS Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BLUE CROSS Metformin-Pioglitazone Product Portfolio
  54. 8.9.5 BLUE CROSS Recent Developments
  55. 8.10 Aurobindo Pharma
  56. 8.10.1 Aurobindo Pharma Company Information
  57. 8.10.2 Aurobindo Pharma Business Overview
  58. 8.10.3 Aurobindo Pharma Metformin-Pioglitazone Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Aurobindo Pharma Metformin-Pioglitazone Product Portfolio
  60. 8.10.5 Aurobindo Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst